Synthesis of Pyrazole-containing Derivatives as New Potential anti-tubercular
Keywords:
Pyrazole Derivative, Mycobacterium tuberculosis, MTB BacteriaAbstract
The synthesized all the compounds are found in good yield and highly sensitive compounds, 1-{3-[5H-pyrazol- sulphonyl] -2 methyl amino benzyloxy-4,5 dihydro-3H pyrazol 4yl} ethanone (I) occurs 12.6 gm. Similarly 1-{5-[4-Dimethylamino-3-(4H-pyrazole-3-sulf inyl)-benzyloxy]-3H-pyrazol-3-yl}-ethanone and 1-(3-{2-Dimethylamino-5-[dimethylene-(4H-pyrazol-3-yl)-sulfanyl]-benzyloxy}-4H-pyrazol-4-yl)-ethanone occurs as 1.2 gm and 14.1 gm respectively. The synthesized compounds (I), (II), (III), 1-{3-[5H pyrazole sulphonyl-2 methyl amino benzyloxy-4,5 dihydro-3H pyrazole-4yl}ethenone, have been shows remarkable progress without and with streptomycin 94.80% of resistance against the straining MTB bacteria. Compounds 1-{5-[4-Dimethylamino-3-(4H-pyrazole-3-sulf inyl)-benzyloxy]-3H-pyrazol-3-yl}-ethanone,1-(3-{2-Dimethylamino-5-[dimethylene-(4H-pyrazole-3-yl)-sulf inyl]-benzyloxy}-4H-pyrazol-4-yl)-ethanoneand1-{3-[1-(4-Chloro-4H-pyrazol-3-ylmethyl)-piperidin-4-ylamino]-6-fluoro-3H-indazol-5-yl}-ethanone is more reliable than streptomycin and shows 94.9% resistance power with MTB bacteria.
References
World Health Organization, treatment of tuberculosis Guidelines, 4th edition, World Health Organization, (2010).
Ethambutol, Chemical Entities of Biological Interest European Bioinformatics Institute UK. (2018). 18 August. Retrieved April 26, (2021).
Yendapally R. and Lee R. E., Bioorg Med. Chem. Lett., 18, 1607-1611 (2008).
Bernstein J. Lott W. A., Steinberg B. A. and Yale H. L., Am. Rev. Tuber., 65, 357, Pharmacotherapy, 21, 1037-1045 (2001).
Sycheva T. P., Palovat T. N. and Shchukina N. M. Pharm. Chem. J., 6, 696-698 (1972).
Fox, H. H. Science 116(952), 129-134. (b) Spala S., Magoulas I. Tsapas G. Vaonas C, Perit. Dial. Int, 20, 47-52 (2000).
Yeager R. L., Munroe W. C. and Dessau F. I. Am. Rev. Tuberc., 65, 523-546 (1952).
Kushner I., Dallalan H., Sanjurjo J. L., Bach F. L., Safir S. R., Smith K. V., William J. H. Jr, J. Am. Chem. Soc. 74,
-3621, (1952).
Steele, M. A. and Des Prez, R. M. Chest, 94, 845-850. (1988).
Hoffman P. S. Ant. Gr. 516, 752-767 (2002).
Sensi P. Rev. Infect. Dis., 5, S402-S406. (1983).
Hanman E., Belgiaj A. M., Ghoem M. M. and J. Microchem 77, 53-62 (2004).
Singh B., Mitshoudo D. A., Br. Med. J., 1, 130-132 (1954).
Zhu M., Burman W. J., Jaresko G. S., Benning S. E., Jelliffe R. W., Peloquin C. A. Pharmacotherapy, 21, 1037-
(2001).
M. D. Iseman, N. Engl. J. Med., 329, 784-790 (1993).
Veronique Durostis, Clifton F. Barry, Curr. Clinical Pharmacology, 5, 96-114 (2010).
Onyebujjo P., Zumla A., Ribeiro I., Rustomjee R., Mwaba P., Gomes M., Grange J. M. Bull. World Health Organization, 83, 857-865 (2005).
World Health Organization, The Five Elements of DOTS, WHO, (2007).
Anand, N. Ramakrishna K. K., Gupta G., Chaturvedi M. P., Singh V., Srivastava S., Sharma K. K. Rai P., Ramachandran
N., Dudweik R., Gupta A., K. Kumar V., Pandey B., Shukla S., Pandey P. K., Lal S. K. and Tripathi R. P. J., ACS Med. Chem. Lett., 4, 958-963 (2013).
Trivedi A., Dodiya D., Surani J., Jarasania S., Matukhiya H., Ravat N. and Shah V. Arch. Pharm. Chem. Life Sci., 341, 433-459 (2008).
Wang H., Li L., Lin W., Xu P., Huang Z. and Shi D., “An Efficient Synthesis of Pyrrolo [2, 3, 4-kl] acridin-1-oneDerivatives Catalyzed by p-toluen”, 14(17), 4598-4601, (2012).
Jaime R. U., Jones D., Ashkin D., Elsan H. S., Bernstein D., Anthony P. A. and Arthur E. P., “Anti-tuberculosis Drug- Induced Hepatotoxicity”, J. Am. of Resp. and Critical Care Medicine, 157(6), 1871-1876, (1998).
Ellard G. A., Humphries M. J. and Allen B. W., “Cerebrospinal Fluid Drug Concentrations and the Treatment of Tuberculous Meningitis”, American Review of Respiratory Disease, 138(4), 650-655, (1993).
Kouzi A. A., Nuzum L., Lounis N., Guillemont J. and Andries K., “The challenge of new drug discovery for tuberculosis”. 469 (2008).
Sahu S. K., Banerjee M., Samantary A., Behera C. and Azam M. A., “Tropical”, Journal of Pharmaceutical Res., 7(2), 961-968 (2008).
Mishra P., Saxena A., Keskar M., and Saxena V., “Derivatives, ISON Pyridazines, Synthsis, Characterization and anti- inflammatory activity of cinnolines (pyrazole)”, Journal of pharmacy and biological sciences 2, 77-82, (2015).
Sahu S. K., Banerjee M., Samantary A., Behera C., Azam M. A., “Tropical”, Journal of Pharmaceutical Res., 7, 961-968 (2008).
Shoman M. E., Mohamed A. A., Omar A. M., Hassan F. H., Morsy M. and Eur. J Med Chem, 44, 3008–3076, (2009).
Shomefi F. Bizzarri B. Manna F., Bolsao A. Seccl D, Chinmeti P. Bioorg Med Chem Lett., 15, 603-607, (2005).
Moged A., Berghot E., Mowad B., Eur J Pharm Sci, 20, 173-179, (2003).
Sheriff A. F. R., Ramsson “POV substituted pyrazoles”, Bioorg. Med. Chem. 2767-2776, (2010).
Kaliraha B., Lingespan B. Rai N. S., “Synthesis of antimicrobial activity studies of some novel pyrazolones carrying pyrimidine moiety”, Indian J. Hetero. Chem, 17, 67-70 (2008).
S. S. Banerjee A. G., Karale B. K., “Synthesis of some biologically active pyrazoles”, Indian J. Hetero. Chem, 19, 325-328(2010).
Downloads
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
